Molecular targets for AIDS therapy.

Article Details

Citation
Copy to clipboard

Mitsuya H, Yarchoan R, Broder S

Molecular targets for AIDS therapy.

Science. 1990 Sep 28;249(4976):1533-44.

PubMed ID
1699273 [ View in PubMed
]
Abstract

The development of antiretroviral therapy against acquired immunodeficiency syndrome (AIDS) has been an intense research effort since the discovery of the causative agent, human immunodeficiency virus (HIV). A large array of drugs and biologic substances can inhibit HIV replication in vitro. Nucleoside analogs--particularly those belonging to the dideoxynucleoside family--can inhibit reverse transcriptase after anabolic phosphorylation. 3'-Azido-2',3'-dideoxythymidine (AZT) was the first such drug tested in individuals with AIDS, and considerable knowledge of structure-activity relations has emerged for this class of drugs. However, virtually every step in the replication of HIV could serve as a target for a new therapeutic intervention. In the future, non-nucleoside-type drugs will likely become more important in the experimental therapy of AIDS, and antiretroviral therapy will exert major effects against the morbidity and mortality caused by HIV.

DrugBank Data that Cites this Article

Drugs